soul trial oral semaglutide cardiovascular outcomes results 2024 and in High-Risk Type 2 Diabetes Canadian Perspectives 2025 Whiteboard on

The World Anti-Doping Agency (WADA) banned BPC-157 effective January 1, 2022, classifying it under the S0 (Unapproved Substances) category

The one exception: Medicare covers GLP-1 medications when prescribed for FDA-approved indications other than weight loss

Never restart semaglutide without medical clearance after surgery

Developed by me as an orally administered, GLP-1dominant dual GLP-1/GIP agonist using a theory-driven, PK/PD-first design paradigm rather than potency-centric SAR

M.JordanaX.Van HummelenP.AlvarezM

GLP-1 non responders are patients who do not achieve expected improvements in blood sugar or weight despite appropriate therapy